KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Deferred Taxes (2016 - 2025)

Idexx Laboratories has reported Deferred Taxes over the past 17 years, most recently at $31.5 million for Q4 2025.

  • Quarterly results put Deferred Taxes at $31.5 million for Q4 2025, up 574.27% from a year ago — trailing twelve months through Dec 2025 was $131.2 million (up 642.3% YoY), and the annual figure for FY2025 was $131.2 million, up 642.3%.
  • Deferred Taxes for Q4 2025 was $31.5 million at Idexx Laboratories, down from $93.2 million in the prior quarter.
  • Over the last five years, Deferred Taxes for IDXX hit a ceiling of $93.2 million in Q3 2025 and a floor of -$33.6 million in Q4 2023.
  • Median Deferred Taxes over the past 5 years was -$2.2 million (2023), compared with a mean of $1.0 million.
  • Biggest five-year swings in Deferred Taxes: crashed 9186.81% in 2022 and later skyrocketed 1461.48% in 2025.
  • Idexx Laboratories' Deferred Taxes stood at -$7.4 million in 2021, then soared by 124.58% to $1.8 million in 2022, then crashed by 1938.74% to -$33.6 million in 2023, then soared by 113.93% to $4.7 million in 2024, then soared by 574.27% to $31.5 million in 2025.
  • The last three reported values for Deferred Taxes were $31.5 million (Q4 2025), $93.2 million (Q3 2025), and $2.5 million (Q2 2025) per Business Quant data.